CS6 antibodies target the CS6 antigen, a colonization factor expressed by Enterotoxigenic Escherichia coli (ETEC), a leading cause of diarrheal disease globally . These antibodies play a critical role in blocking bacterial adhesion to intestinal epithelial cells, preventing infection . CS6 is a heteropolymer composed of two subunits, CssA and CssB, which mediate ETEC binding to host cells .
Fab Fragment: Binds to CS6 antigens via variable domains of heavy (V<sub>H</sub>) and light (V<sub>L</sub>) chains .
Fc Region: Mediates immune effector functions (e.g., phagocytosis) .
Intramuscular administration of CS6-based vaccines (e.g., CssBA + dmLT adjuvant) induced robust immune responses:
Serum IgG/IgA: Peak titers observed on Day 71 post-vaccination .
Mucosal Immunity: Anti-CS6 IgA antibodies detected in lymphocyte supernatants .
A randomized trial testing oral bovine anti-CS6 immunoglobulins (BSIgG) showed:
Group | Moderate-Severe Diarrhea Rate | Efficacy vs Placebo |
---|---|---|
Placebo (n=20) | 70% (14/20) | — |
Anti-CS6 BSIgG | 63% (12/19) | 10% (NS) |
Anti-B7A BSIgG | 35% (7/20) | 50% (p=0.06) |
NS: Not statistically significant. Lack of efficacy for CS6-specific antibodies correlated with low CS6 surface expression on the challenge strain .
PCR-based screening of ETEC isolates revealed:
CS6 was frequently co-expressed with other colonization factors (e.g., CS4, CS5) .
Vaccine Development: CS6 is a candidate for multivalent ETEC vaccines due to its prevalence in endemic regions .
Passive Immunization: Bovine-derived anti-CS6 antibodies showed safety but limited efficacy in human trials .
Antigen Variability: CS6 surface expression levels impact antibody efficacy .
Adjuvant Dependency: Immune responses require potent adjuvants like dmLT .